Univest
Univest
  • Markets
  • Alembic Q1 FY27 Results: Revenue Rs 48 Cr, PAT Rs 15 Cr and Key Highlights

    • August 12, 2026
    • Posted by: Kunal Singla
    • Category: News
    No Comments

    Alembic Q1 FY27 results: Revenue Rs 48 Cr, PAT Rs 15 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

    read more
  • KP Energy Q1 FY27 Results: Revenue Rs 519 Cr, PAT Rs 26 Cr and Key Highlights

    • August 12, 2026
    • Posted by: Lakshit Sharma
    • Category: News
    No Comments

    KP Energy Q1 FY27 results: Revenue Rs 519 Cr, PAT Rs 26 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

    read more
  • Tribhovandas Bhimji Zaveri Q1 FY27 Results: Revenue Rs 840 Cr, PAT Rs 33 Cr and Key Highlights

    • August 12, 2026
    • Posted by: Lakshit Sharma
    • Category: News
    No Comments

    Tribhovandas Bhimji Zaveri Q1 FY27 results: Revenue Rs 840 Cr, PAT Rs 33 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

    read more
  • Vikran Engineering Q1 FY27 Results: Revenue Rs 141 Cr, PAT Rs 3 Cr and Key Highlights

    • August 12, 2026
    • Posted by: Neeraj Pandey
    • Category: News
    No Comments

    Vikran Engineering Q1 FY27 results: Revenue Rs 141 Cr, PAT Rs 3 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

    read more
  • Arkade Developers Q1 FY27 Results: Revenue Rs 146 Cr, PAT Rs 19 Cr and Key Highlights

    • August 12, 2026
    • Posted by: Kunal Singla
    • Category: News
    No Comments

    Arkade Developers Q1 FY27 results: Revenue Rs 146 Cr, PAT Rs 19 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

    read more
  • Pros and Cons of Investing in Dr Lal PathLabs Share: Diagnostic Lab Analysis 2026

    • August 12, 2026
    • Posted by: Ankit Jaiswal
    • Category: News
    No Comments
    Pros and Cons of Investing in Dr Lal PathLabs Share: Diagnostic Lab Analysis 2026

    Five pros including strong North India diagnostic brand and hub-and-spoke model, and four cons including competition from Metropolis and low-cost rivals, of Dr Lal PathLabs share.

    read more
  • Simplex Infrastructure Q1 FY27 Results: Revenue Rs 290 Cr, PAT Rs 10 Cr and Key Highlights

    • August 12, 2026
    • Posted by: Lakshit Sharma
    • Category: News
    No Comments

    Simplex Infrastructure Q1 FY27 results: Revenue Rs 290 Cr, PAT Rs 10 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

    read more
  • Prakash Industries Q1 FY27 Results: Revenue Rs 1,032 Cr, PAT Rs 71 Cr and Key Highlights

    • August 12, 2026
    • Posted by: Lakshit Sharma
    • Category: News
    No Comments

    Prakash Industries Q1 FY27 results: Revenue Rs 1,032 Cr, PAT Rs 71 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

    read more
  • Landmark Cars Q1 FY27 Results: Revenue Rs 1,302 Cr, PAT Rs 14 Cr and Key Highlights

    • August 12, 2026
    • Posted by: Kunal Singla
    • Category: News
    No Comments

    Landmark Cars Q1 FY27 results: Revenue Rs 1,302 Cr, PAT Rs 14 Cr. Key highlights, performance, FY27 outlook. Read full results analysis here.

    read more
  • Pros and Cons of Investing in Aether Industries Share: Specialty Chemical CDMO Analysis

    • August 12, 2026
    • Posted by: Neeraj Pandey
    • Category: News
    No Comments
    Pros and Cons of Investing in Aether Industries Share: Specialty Chemical CDMO Analysis

    Five pros including innovative CDMO model and pharma agrochemical demand, and four cons including customer concentration and capacity scale-up risk, of Aether Industries share.

    read more
  • 1
  • …
  • 733
  • 734
  • 735
  • 736
  • 737
  • …
  • 2,719